Back to Browse Journals » Clinical Interventions in Aging » Volume 2 » Issue 4

Review of long-term adverse effects associated with the use of chemically-modified animal and nonanimal source hyaluronic acid dermal fillers

Authors Paul C Edwards, John E Fantasia

Published Date January 2007 Volume 2007:2(4) Pages 509—519

DOI http://dx.doi.org/10.2147/CIA.S382

Published 3 January 2007

Paul C Edwards1, John E Fantasia2

1Associate Professor (Clinical), Department of Periodontics and Oral Medicine, Pathology and Oncology, University of Michigan School of Dentistry, Ann Arbor MI, USA; 2Chief, Division of Oral Pathology, Department of Dental Medicine, Long Island Jewish Medical Center, New Hyde Park, NY, USA

Abstract: Although only recently introduced, chemically-modified hyaluronic acid dermal fillers have gained widespread acceptance as “redefining” dermal fillers in the fields of dermatology and cosmetic facial surgery. Although hyaluronic acid-based dermal fillers have a low overall incidence of long term side effects, occasional adverse outcomes, ranging from chronic lymphoplasmacytic inflammatory reactions to classic foreign body-type granulomatous reactions have been documented. These long-term adverse events are reviewed.

Keywords: hyaluronic acid, Restylane®, Hylaform®, injectable dermal filler, foreign body reaction, granuloma

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Pharmacokinetics and pharmacodynamics of acetylsalicylic acid after intravenous and oral administration to healthy volunteers

Nagelschmitz J, Blunck M, Kraetzschmar J, Ludwig M, Wensing G, Hohlfeld T

Clinical Pharmacology: Advances and Applications 2014, 6:51-59

Published Date: 19 March 2014

Population pharmacokinetics of olprinone in healthy male volunteers

Kunisawa T, Kasai H, Suda M, Yoshimura M, Sugawara A, Izumi Y, Iida T, Kurosawa A, Iwasaki H

Clinical Pharmacology: Advances and Applications 2014, 6:43-50

Published Date: 4 March 2014

Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy

Gold M, Lorenzl S, Stewart AJ, Morimoto BH, Williams DR, Gozes I

Neuropsychiatric Disease and Treatment 2012, 8:85-93

Published Date: 9 February 2012

Synthesis and characterization of electrospun polyvinyl alcohol nanofibrous scaffolds modified by blending with chitosan for neural tissue engineering

Naghavi Alhosseini S, Moztarzadeh F, Mozafari M, Asgari S, Dodel M, Samadikuchaksaraei A, Kargozar S, Jalali N

International Journal of Nanomedicine 2012, 7:25-34

Published Date: 4 January 2012

Detemir as a once-daily basal insulin in type 2 diabetes

Nelson SE

Clinical Pharmacology: Advances and Applications 2011, 3:27-37

Published Date: 18 August 2011

A study on the preparation and characterization of plasmid DNA and drug-containing magnetic nanoliposomes for the treatment of tumors

Wang Z-Y, Wang L, Zhang J, Li Y-T, Zhang D-S

International Journal of Nanomedicine 2011, 6:871-875

Published Date: 27 April 2011